A method for culturing human umbilical cord mesenchymal stem cells without animal-derived components
By using recombinant matrix proteins and chemically defined nutrients to replace animal-derived components, the safety and stability issues in human umbilical cord mesenchymal stem cell culture were resolved, achieving highly efficient cell expansion.
Patent Information
- Application Number
- CN202611522821.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-29
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, the in vitro culture of human umbilical cord mesenchymal stem cells relies on animal-derived components such as fetal bovine serum and human platelet lysates, which pose risks of pathogen transmission, unstable components, and difficulty in standardization, affecting the safety and quality control of cell products.
Recombinant expression matrix proteins (recombinant human fibronectin, recombinant human fibronectin, recombinant human laminin 511 and recombinant human type III collagen) were used to replace natural adhesion proteins, and chemically defined amino acids, vitamins, trace elements and growth factors were formulated to form a culture medium without animal-derived components, thereby achieving efficient cell adhesion and expansion.
It achieves cell culture without animal-derived components, avoids the risk of pathogen transmission, ensures the biosafety and quality stability of cell products, and the cell adhesion effect is comparable to traditional methods. The amplification efficiency is better than traditional methods, reaching a proliferation fold of about 14 times in 72 hours.
Smart Images

Figure CN123107920A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a method for culturing human umbilical cord mesenchymal stem cells without animal-derived components. Background Technology
[0002] Human umbilical cord mesenchymal stem cells (hUC-MSCs) have broad application prospects in regenerative medicine and cell therapy due to their abundant source, strong proliferative capacity, low immunogenicity, and multi-lineage differentiation potential. However, achieving efficient in vitro expansion of hUC-MSCs is one of the key technical bottlenecks restricting their clinical translation.
[0003] Currently, the in vitro culture of hUC-MSCs typically employs a basal medium (such as DMEM, DMEM / F12, MEM-α, etc.) supplemented with a certain proportion of fetal bovine serum (FBS) or human platelet lysate (hPL). This protocol maintains the adhesion and proliferation of umbilical cord mesenchymal stem cells through adhesion proteins and growth factors from naturally extracted components such as FBS or hPL. While relatively simple to operate, it has the following significant drawbacks: First, FBS is an animal-derived component, and the foreign pathogens it carries (such as viruses, prions, etc.) may be transmitted to patients through cell products, triggering an immune response or increasing the risk of infection. The European Medicines Agency (EMA, formerly EMEA) has clearly stated that alternatives without foreign components should be given priority (EMEA / CHMP / 410869 / 2006). Although hPL is a human-derived component, as a blood product, it still carries the potential risk of pathogen transmission, and there are significant batch-to-batch differences in hPL from different donors, affecting the stability of the culture system.
[0004] Second, both FBS and hPL are natural biological extracts with complex compositions and significant differences due to different batches, making it difficult to standardize cell culture performance and hindering quality control of clinical-grade cell products.
[0005] Third, FBS and hPL contain thousands of unidentified proteins, lipids, and small molecule metabolites, some of which may have unpredictable effects on the phenotype and differentiation potential of stem cells.
[0006] In the prior art, some studies have attempted to develop serum-free culture media for the culture of mesenchymal stem cells. For example, CN117535237A discloses a human umbilical cord mesenchymal stem cell culture medium, which achieves serum-free culture by adding components such as reduced glutathione, epidermal growth factor, basic fibroblast growth factor, recombinant human insulin, hyaluronic acid, and fibronectin. However, this scheme uses only a single adhesion protein (fibronectin), making it difficult to match the adhesion effect with serum-containing schemes. CN111304163A discloses a culture medium that improves the adhesion performance and proliferation rate of umbilical cord mesenchymal stem cells by adding β-sitosterol and catechins, but its composition is still based on basal culture medium, and the chemical limitation of nutrient components is limited.
[0007] Therefore, there is an urgent need to develop a culture protocol that is completely independent of animal or human blood extracts, has clearly defined components, and can achieve efficient adhesion and amplification of hUC-MSCs. Summary of the Invention
[0008] The purpose of this invention is to overcome the shortcomings of the prior art and provide a method for culturing human umbilical cord mesenchymal stem cells without animal-derived components. Without introducing any animal-derived components, the method maintains the adhesion of umbilical cord mesenchymal stem cells by recombinantly expressing a combination of matrix proteins, and combines chemically defined amino acids, vitamins, trace elements, lipids and recombinantly expressed growth factors to achieve efficient in vitro expansion of human umbilical cord mesenchymal stem cells.
[0009] The technical solution of the present invention is as follows: A method for culturing human umbilical cord mesenchymal stem cells without animal-derived components, comprising the following steps: Step 1: Prepare the recombinant extracellular matrix stock solution: Redissolve 511 g / L of recombinant human fibronectin, recombinant human hyalin and recombinant human laminin in sterile water for injection to 1 g / L, and redissolve recombinant human type III collagen and recombinant human fetoglobulin in sterile purified water to 20 g / L. Store the stock solution at -20°C. Step 2, prepare growth factor stock solution: reconstitute recombinant human EGF, recombinant human bFGF, recombinant human PDGF-AA, recombinant human PDGF-BB, recombinant human TGF-β3, recombinant human VEGF165 and recombinant human LIF to 1 g / L with sterile water for injection, and dilute to 10 mg / L with DPBS respectively. Store the stock solution at -20℃. Step 3, prepare the concentrates: Prepare insulin concentrate (recombinant human insulin 10 g / L, pH 2.0, 1000×); concentrate 1 (riboflavin 1 g / L, biotin 0.05 g / L, lipoic acid 0.2 g / L, linoleic acid 0.1 g / L, oleic acid 0.1 g / L, pH 12.0, 1000×); concentrate 2 (sodium selenite 1 g / L, ammonium molybdate tetrahydrate 0.4 g / L, sodium metavanadate 0.05 g / L, pH 12.0, 100000×); concentrate 3 (copper sulfate pentahydrate 5 g / L, manganese chloride tetrahydrate 0.05 g / L, nickel sulfate hexahydrate 0.05 g / L, stannous chloride dihydrate 0.4 g / L, pH 1.0, 100000×). Step 4, prepare the complete culture medium: Weigh 80% of the final volume of water for injection, and add amino acids, vitamins, inorganic salts and trace elements, lipids, other components, and the stock solution and concentrate prepared in steps 1 to 3 in sequence, and mix well. Step 5, adjust pH and osmotic pressure: Adjust the pH to 7.0-7.4 with hydrochloric acid or sodium hydroxide, take a sample to measure the osmotic pressure, add sodium chloride to adjust the osmotic pressure to 300-340 mOsm / kg, and bring the volume to the final volume; Step 6, filtration and sterilization: Sterilize by filtration through a double-layer filter membrane of 0.45 μm and 0.2 μm, and store at 2-8℃.
[0010] Preferably, the final concentrations of each amino acid component in step four are: arginine hydrochloride 100 mg / L, asparagine monohydrate 50 mg / L, cystine dihydrochloride 20 mg / L, histidine dihydrochloride 30 mg / L, isoleucine 50 mg / L, leucine 50 mg / L, lysine hydrochloride 60 mg / L, methionine 15 mg / L, phenylalanine 30 mg / L, threonine 50 mg / L, tryptophan 10 mg / L, tyrosine 30 mg / L, valine 50 mg / L, glutamine 300 mg / L, acetylcysteine 150 mg / L, taurine 125 mg / L, and γ-aminobutyric acid 10 mg / L.
[0011] Preferably, the final concentrations of each vitamin component in step four are: choline chloride 20 mg / L, calcium pantothenate 5 mg / L, calcium folinate hydrate 1 mg / L, nicotinamide 5 mg / L, pyridoxal hydrochloride 5 mg / L, thiamine hydrochloride 5 mg / L, cyanocobalamin 0.1 mg / L, inositol 10 mg / L, and disodium tocopherol phosphate 2 mg / L.
[0012] Preferably, the final concentrations of each component of the inorganic salts and trace elements in step four are: potassium chloride 400 mg / L, calcium nitrate tetrahydrate 500 mg / L, magnesium sulfate 150 mg / L, sodium bicarbonate 2450 mg / L, disodium hydrogen phosphate 150 mg / L, zinc sulfate heptahydrate 0.5 mg / L, ferric ammonium citrate 1 mg / L, lithium chloride 4 mg / L, and sodium metasilicate nonahydrate 1 mg / L.
[0013] Preferably, the final concentration of each lipid component in step four is: soybean lecithin 0.5 mg / L.
[0014] Preferably, the final concentrations of the other components in step four are: glucose 2000 mg / L, sodium pyruvate 110 mg / L, malic acid 50 mg / L, HEPES 3000 mg / L, recombinant human serum albumin 1000 mg / L, recombinant human deferferrin 30 mg / L, ethanolamine hydrochloride 10 mg / L, sodium β-glycerophosphate 300 mg / L, sodium hypoxanthine 6 mg / L, thymidine 10 mg / L, nicotinamide mononucleotide 10 mg / L, and flavin adenine disodium salt dihydrate 6 mg / L.
[0015] Preferably, the amount of mother liquor added in step four is: 10 mg / L recombinant human EGF 0.5 mL / L, 10 mg / L recombinant human bFGF 0.5 mL / L, 10 mg / L recombinant human PDGF-AA 0.5 mL / L, 10 mg / L recombinant human PDGF-BB 0.5 mL / L, 10 mg / L recombinant human TGF-β3 0.05 mL / L, 10 mg / L recombinant human VEGF165 1 mL / L, 10 mg / L recombinant human LIF 1 mL / L, 1 g / L recombinant human fibronectin 5 mL / L, 1 g / L recombinant human hyalin 5 mL / L, 1 g / L recombinant human laminin 511 1 mL / L, 20 g / L recombinant human type III collagen 5 mL / L, 20 g / L recombinant human fetal globulin 5 mL / L, insulin concentrate 1 mL / L, concentrate 1 1 mL / L, concentrate 2 0.01 mL / L. mL / L, concentrate 3 0.01 mL / L.
[0016] The concentration ranges of each component in this invention are as follows: Matrix proteins: Recombinant human fibronectin 2.5-10 mg / L, recombinant human fibronectin 2.5-10 mg / L, recombinant human laminin 511 0.5-2 mg / L, recombinant human type III collagen 50-200 mg / L, recombinant human fetoglobulin 50-200 mg / L.
[0017] Amino acids: Arginine hydrochloride 20-500 mg / L, Asparagine monohydrate 10-250 mg / L, Cystine dihydrochloride 4-100 mg / L, Histidine dihydrochloride 6-150 mg / L, Isoleucine 10-250 mg / L, Leucine 10-250 mg / L, Lysine hydrochloride 12-300 mg / L, Methionine 3-75 mg / L, Phenylalanine 6-150 mg / L, Threonine 10-250 mg / L, Tryptophan 2-50 mg / L, Tyrosine 6-150 mg / L, Valine 10-250 mg / L, Glutamine 60-1500 mg / L, Acetylcysteine 30-750 mg / L, Taurine 25-625 mg / L, Gamma-aminobutyric acid 2-50 mg / L.
[0018] Vitamins: Biotin 0.01-0.25 mg / L, choline chloride 4-100 mg / L, calcium pantothenate 1-25 mg / L, calcium leucovorin hydrate 0.2-5 mg / L, nicotinamide 1-25 mg / L, pyridoxal hydrochloride 1-25 mg / L, riboflavin 0.2-5 mg / L, thiamine hydrochloride 1-25 mg / L, cyanocobalamin 0.02-0.5 mg / L, inositol 2-50 mg / L, disodium tocopherol phosphate 0.4-10 mg / L.
[0019] Inorganic salts and trace elements: Sodium chloride 6000-6800 mg / L, potassium chloride 300-500 mg / L, calcium nitrate tetrahydrate 400-600 mg / L, magnesium sulfate 100-200 mg / L, sodium bicarbonate 1200-3700 mg / L, disodium hydrogen phosphate 100-200 mg / L, copper sulfate pentahydrate 0.01-0.25 mg / L, zinc sulfate heptahydrate 0.1-2.5 mg / L, sodium selenite 0.002-0.05 mg / L, ferric ammonium citrate 0.2-5 mg / L, lithium chloride 0.8-20 mg / L, manganese chloride tetrahydrate 0.0001-0.0025 mg / L, nickel sulfate hexahydrate 0.0001-0.0025 mg / L, ammonium molybdate tetrahydrate 0.0008-0.02 mg / L. mg / L, sodium metavanadate 0.0001-0.0025 mg / L, stannous chloride dihydrate 0.0008-0.02 mg / L, sodium metasilicate nonahydrate 0.2-5 mg / L.
[0020] Lipids: Lipoic acid 0.04-1 mg / L, linoleic acid 0.02-0.5 mg / L, oleic acid 0.02-0.5 mg / L, soybean lecithin 0.1-2.5 mg / L.
[0021] Growth factors: Recombinant human EGF 0.001-0.025 mg / L, recombinant human bFGF 0.001-0.025 mg / L, recombinant human PDGF-AA 0.001-0.025 mg / L, recombinant human PDGF-BB 0.001-0.025 mg / L, recombinant human TGF-β3 0.0001-0.0025 mg / L, recombinant human VEGF165 0.002-0.05 mg / L, recombinant human LIF 0.002-0.05 mg / L.
[0022] Other components: glucose 1000-4000 mg / L, sodium pyruvate 55-220 mg / L, malic acid 25-100 mg / L, HEPES 1500-6000 mg / L, recombinant human serum albumin 500-2000 mg / L, recombinant human insulin 5-20 mg / L, recombinant human deferferrin 15-60 mg / L, ethanolamine hydrochloride 5-20 mg / L, sodium β-glycerophosphate 200-400 mg / L, sodium hypoxanthine 3-12 mg / L, thymidine 5-20 mg / L, nicotinamide mononucleotide 5-20 mg / L, flavin adenine disodium salt dihydrate 3-12 mg / L.
[0023] Due to the application of the above technical solution, the beneficial effects of this invention compared with the prior art are as follows: 1. This invention uses recombinant expressed matrix proteins (recombinant human fibronectin, recombinant human fibronectin, recombinant human laminin 511, recombinant human type III collagen and recombinant human fetal globulin) to replace the natural adhesion proteins in FBS and hPL. All components are recombinantly expressed or chemically synthesized, with clearly defined components, avoiding the risk of transmission of animal-derived pathogens and xenogeneic immunogenicity, and improving the biosafety of cell products.
[0024] 2. This invention covers multiple cell adhesion receptor pathways, such as integrin α5β1 (fibronectin), αvβ3 / αvβ5 (fibronectin), and α6β1 (lamin 511), through the synergistic combination of five recombinant matrix proteins. The adhesion effect is comparable to that of traditional culture programs that add human platelet lysate.
[0025] 3. By optimizing the types and ratios of components such as amino acids, vitamins, trace elements, lipids and growth factors, this invention achieves a cell proliferation rate of approximately 14 times in 72 hours, which is superior to the basal medium + 10% FBS regimen (approximately 9.5 times) and the basal medium + 5% hPL regimen (approximately 10.5 times).
[0026] 4. All components of this invention are chemically defined or recombinantly expressed, avoiding batch-to-batch differences in natural biological extracts and facilitating the standardization of the culture process and quality control. Attached Figure Description
[0027] Figure 1 This is a microscope image of umbilical cord mesenchymal stem cells in embodiment A of the present invention.
[0028] Figure 2 This is a microscope image of umbilical cord mesenchymal stem cells in embodiment B of the present invention.
[0029] Figure 3 This is a microscope image of umbilical cord mesenchymal stem cells in embodiment C of the present invention.
[0030] Figure 4 This is a comparison chart of the expansion fold of umbilical cord mesenchymal stem cells under three different culture schemes in the embodiments of the present invention. Detailed Implementation
[0031] The following examples describe the disclosure of this invention in more detail. These examples are merely illustrative, as various modifications and variations will be apparent to those skilled in the art within the scope of this disclosure. Unless otherwise stated, all parts, percentages, and ratios reported in the following examples are based on weight, and all reagents used in the examples are commercially available or synthesized by conventional methods and can be used directly without further processing. The instruments used in the examples are also commercially available.
[0032] The present invention will be further described in detail below with reference to specific embodiments. These embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.
[0033] Example 1: This embodiment provides a formulation for a culture medium for human umbilical cord mesenchymal stem cells without animal-derived components.
[0034] Step 1: Preparation of recombinant extracellular matrix stock solution Reconstitute the recombinant human fibronectin lyophilized powder, recombinant human fibronectin lyophilized powder, and recombinant human laminin 511 lyophilized powder to 1 g / L using sterile water for injection; reconstitute the recombinant human type III collagen lyophilized powder and recombinant human placental protein lyophilized powder to 20 g / L using sterile purified water. After aliquoting, store the mother solutions at -20°C, avoiding repeated freeze-thaw cycles.
[0035] Step 2: Preparation of growth factor stock solution Reconstitute recombinant human EGF, recombinant human bFGF, recombinant human PDGF-AA, recombinant human PDGF-BB, recombinant human TGF-β3, recombinant human VEGF165, and recombinant human LIF lyophilized powder to 1 g / L with sterile water for injection. Dilute the reconstituted solution to 10 mg / L with DPBS, aliquot, and store at -20°C.
[0036] Step 3: Preparation of other concentrated solutions Prepare the concentrated solutions according to Table 1 below and adjust the pH accordingly: Table 1:
[0037] Step 4: Preparation of complete culture medium Weigh out 80% of the final volume of water for injection and add it to each component solute or concentrate in sequence according to the following procedure: Arginine hydrochloride 100 mg / L, asparagine monohydrate 50 mg / L, cystine dihydrochloride 20 mg / L, histidine dihydrochloride 30 mg / L, isoleucine 50 mg / L, leucine 50 mg / L, lysine hydrochloride 60 mg / L, methionine 15 mg / L, phenylalanine 30 mg / L, threonine 50 mg / L, tryptophan 10 mg / L, tyrosine 30 mg / L, valine 50 mg / L, glutamine 300 mg / L, acetylcysteine 150 mg / L, taurine 125 mg / L, γ-aminobutyric acid 10 mg / L, choline chloride 20 mg / L, calcium pantothenate 5 mg / L, calcium leucovorin hydrate 1 mg / L, nicotinamide 5 mg / L, pyridoxal hydrochloride 5 mg / L, thiamine hydrochloride 5 mg / L, cyanocobalamin 0.1 mg / L, inositol 10 mg / L, disodium tocopheryl phosphate 2 mg / L mg / L, potassium chloride 400 mg / L, calcium nitrate tetrahydrate 500 mg / L, magnesium sulfate 150 mg / L, sodium bicarbonate 2450 mg / L, disodium hydrogen phosphate 150 mg / L, zinc sulfate heptahydrate 0.5 mg / L, ferric ammonium citrate 1 mg / L, lithium chloride 4 mg / L, sodium metasilicate nonahydrate 1 mg / L, soybean lecithin 0.5 mg / L, glucose 2000 mg / L, sodium pyruvate 110 mg / L, malic acid 50 mg / L, HEPES 3000 mg / L, recombinant human serum albumin 1000 mg / L, recombinant human deferferrin 30 mg / L, ethanolamine hydrochloride 10 mg / L, β-glycerophosphate sodium 300 mg / L, hypoxanthine sodium 6 mg / L, thymidine 10 mg / L, nicotinamide mononucleotide 10 mg / L, and flavin adenine disodium salt dihydrate 6 mg / L. mg / L; where flavin adenine disodium salt dihydrate is flavin adenine dinucleotide disodium salt hydrate (FAD disodium salt hydrate).
[0038] The following amounts of stock solution were added: 10 mg / L recombinant human EGF 0.5 mL / L, 10 mg / L recombinant human bFGF 0.5 mL / L, 10 mg / L recombinant human PDGF-AA 0.5 mL / L, 10 mg / L recombinant human PDGF-BB 0.5 mL / L, 10 mg / L recombinant human TGF-β3 0.05 mL / L, 10 mg / L recombinant human VEGF165 1 mL / L, 10 mg / L recombinant human LIF 1 mL / L, 1 g / L recombinant human fibronectin 5 mL / L, 1 g / L recombinant human hyalin 5 mL / L, 1 g / L recombinant human laminin 511 1 mL / L, 20 g / L recombinant human type III collagen 5 mL / L, 20 g / L recombinant human fetal globulin 5 mL / L, insulin concentrate 1 mL / L, concentrate 11 mL / L, concentrate 2 0.01 mL / L, concentrate 3 0.01 mL / L.
[0039] Step 5: Adjust pH and osmotic pressure After the solute has fully dissolved and the concentrate has been mixed evenly, adjust the pH to 7.0-7.4 with hydrochloric acid or sodium hydroxide. Make up to 95% of the final volume with water for injection, take a sample to measure the osmotic pressure, and adjust the osmotic pressure to 300-340 mOsm / kg with sodium chloride according to the measurement results. Make up to the final volume with water for injection.
[0040] Step Six: Filtration and Sterilization The prepared culture medium was sterilized by filtration through a double-layer filter membrane of 0.45 μm and 0.2 μm, and stored at 2-8℃.
[0041] Cell adhesion effect: P3 generation human umbilical cord mesenchymal stem cells were seeded at a density of 5 × 10³ cells / cm² in three culture dishes, using the following three culture protocols: Option A (Control): Basal culture medium + 5% human platelet lysate.
[0042] Scheme B (the present invention): The culture medium (containing the recombinant matrix protein combination) prepared in Example 1.
[0043] Option C (Comparative): The culture medium prepared in Example 1, but without the addition of the recombinant matrix protein combination.
[0044] After inoculation, the cells were incubated at 37°C in a 5% CO2 incubator for 24 hours, and the cell adhesion morphology was observed under an inverted microscope.
[0045] The results show that: Scheme A (such as...) Figure 1 As shown) and Scheme B (as shown) Figure 2In scheme C (as shown), cells adhered to the culture medium within 24 hours, exhibiting a typical spindle-shaped or polygonal extension morphology, with adhesion rates exceeding 95%. The adhesion effects of both schemes were comparable. Figure 3 As shown in the figure, due to the lack of matrix protein composition, the cell adhesion rate was only 30-40%, and the cells spread poorly, with some cells appearing in a round, suspended state. This result indicates that the recombinant matrix protein composition of the present invention can effectively replace the adhesion proteins in human platelet lysate, maintaining the adhesion of umbilical cord mesenchymal stem cells.
[0046] Cell expansion efficiency: P3 generation human umbilical cord mesenchymal stem cells were seeded at a density of 8 × 10³ cells / cm² in three culture systems, using the following three culture protocols: Option 1 (Control 1): Basal culture medium + 10% MSC-qualified fetal bovine serum.
[0047] Option 2 (Control 2): Basal culture medium + 5% human platelet lysis buffer.
[0048] Scheme 3 (the present invention): The culture medium prepared in Example 1.
[0049] Each group was set up with three replicates. After culturing in a 37°C, 5% CO2 incubator for 72 hours, the number of viable cells was counted by trypan blue staining, and the cell proliferation rate was calculated.
[0050] Combination Figure 4 As shown in Table 2 below: Table 2:
[0051] The results showed that the cell expansion efficiency of the animal-free culture protocol of the present invention was significantly better than that of the traditional fetal bovine serum culture protocol (approximately 47.4% higher) and the human platelet lysate culture protocol (approximately 33.3% higher).
[0052] principle: Adhesion Mechanism: Human umbilical cord mesenchymal stem cells express multiple integrin receptors on their surface, including α5β1, αvβ3, αvβ5, and α6β1. In the recombinant matrix protein combination of this invention, fibronectin mainly binds to integrin α5β1 through its RGD sequence, fibronectin binds to integrin αvβ3 / αvβ5 through its RGD sequence, and laminin 511 binds to integrin α6β1 through its LG domain. Type III collagen and fetoglobulin synergistically enhance cell adhesion and spreading by providing additional extracellular matrix support and growth factor carrier functions. The combined use of multiple adhesion proteins covers a broader range of integrin signaling pathways, enabling adhesion effects to reach or exceed the levels of adhesion proteins in natural serum and platelet lysates.
[0053] Mechanism of proliferation promotion: In the culture medium of this invention, recombinant human EGF promotes cell proliferation through the EGFR signaling pathway; bFGF activates the MAPK / ERK cascade through the FGFR signaling pathway, promoting cell division and maintaining stem cell stemness; PDGF-AA and PDGF-BB promote cell survival and proliferation through the PDGFRα / β signaling pathway; VEGF165 promotes cell migration and survival through the VEGFR2 signaling pathway; TGF-β3 and LIF play important roles in maintaining the undifferentiated state of stem cells. The combined use of multiple growth factors can simultaneously activate multiple proliferation signaling pathways, producing a synergistic effect.
[0054] Metabolic support mechanisms: High concentrations of glutamine (300 mg / L) provide cells with sufficient carbon and nitrogen sources; acetylcysteine and taurine provide antioxidant protection, reducing oxidative stress damage to cells; trace elements such as sodium selenite, copper sulfate, and zinc sulfate participate in cell metabolism as cofactors for various enzymes; lipids such as linoleic acid and oleic acid provide raw materials for cell membrane synthesis; recombinant human insulin promotes the uptake and utilization of glucose and amino acids; and recombinant human deferferrin provides safe transport of iron ions.
[0055] The synergistic effect of the above three mechanisms enables the present invention to achieve cell expansion efficiency superior to traditional serum-containing culture protocols without introducing any animal-derived components.
[0056] The present invention has been illustrated with the above embodiments to describe the detailed process steps and conditions. However, the present invention is not limited to the detailed process equipment and process flow described above, that is, it does not mean that the present invention must rely on the detailed process equipment and process flow described above to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent substitutions of raw materials, structural changes, additions of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0057] The above embodiments are only for illustrating the technical concept and features of the present invention. Their purpose is to enable those skilled in the art to understand the content of the present invention and implement it. They should not be used to limit the scope of protection of the present invention. All equivalent changes or modifications made in accordance with the spirit and essence of the present invention should be covered within the scope of protection of the present invention.
Claims
1. A method for culturing human umbilical cord mesenchymal stem cells without animal-derived components, characterized by: Includes the following steps: Step 1: Prepare the recombinant extracellular matrix stock solution: Redissolve 511g / L of recombinant human fibronectin, recombinant human hyalin and recombinant human laminin in sterile water for injection to 1 g / L, and redissolve recombinant human type III collagen and recombinant human fetoglobulin in sterile purified water to 20 g / L. Step 2, prepare growth factor stock solution: reconstitute recombinant human EGF, recombinant human bFGF, recombinant human PDGF-AA, recombinant human PDGF-BB, recombinant human TGF-β3, recombinant human VEGF165 and recombinant human LIF with sterile water for injection to 1 g / L, and dilute with DPBS to 10 mg / L respectively; Step 3, prepare the concentrate: Prepare insulin concentrate, concentrate 1, concentrate 2 and concentrate 3 respectively; wherein, concentrate 1 contains riboflavin, biotin, lipoic acid, linoleic acid and oleic acid; concentrate 2 contains sodium selenite, ammonium molybdate tetrahydrate and sodium metavanadate; concentrate 3 contains copper sulfate pentahydrate, manganese chloride tetrahydrate, nickel sulfate hexahydrate and stannous chloride dihydrate; Step 4, prepare the complete culture medium: Weigh 80% of the final volume of water for injection, and add amino acids, vitamins, inorganic salts and trace elements, lipids, other components, and the stock solution and concentrate prepared in steps 1 to 3 in sequence, and mix well. Step 5: Adjust the pH to 7.0-7.4, adjust the osmotic pressure to 300-340 mOsm / kg, and bring the volume to a final volume. Step 6: Sterilize by filtration through a double-layer filter membrane of 0.45 μm and 0.2 μm.
2. The method of claim 1, wherein: The final concentrations of recombinant human fibronectin, recombinant human fibronectin, recombinant human laminin 511, recombinant human type III collagen, and recombinant human fetoglobulin in the complete culture medium were 2.5-10 mg / L, 0.5-2 mg / L, 50-200 mg / L, and 50-200 mg / L, respectively.
3. The method according to claim 1, characterized in that: The amino acids include arginine hydrochloride 20-500 mg / L, asparagine monohydrate 10-250 mg / L, cystine dihydrochloride 4-100 mg / L, histidine dihydrochloride 6-150 mg / L, isoleucine 10-250 mg / L, leucine 10-250 mg / L, lysine hydrochloride 12-300 mg / L, methionine 3-75 mg / L, phenylalanine 6-150 mg / L, threonine 10-250 mg / L, tryptophan 2-50 mg / L, tyrosine 6-150 mg / L, valine 10-250 mg / L, glutamine 60-1500 mg / L, acetylcysteine 30-750 mg / L, taurine 25-625 mg / L, and γ-aminobutyric acid 2-50 mg / L.
4. The method according to claim 1, characterized in that: The vitamins mentioned include biotin 0.01-0.25 mg / L, choline chloride 4-100 mg / L, calcium pantothenate 1-25 mg / L, calcium leucovorin hydrate 0.2-5 mg / L, nicotinamide 1-25 mg / L, pyridoxal hydrochloride 1-25 mg / L, riboflavin 0.2-5 mg / L, thiamine hydrochloride 1-25 mg / L, cyanocobalamin 0.02-0.5 mg / L, inositol 2-50 mg / L, and disodium tocopherol phosphate 0.4-10 mg / L.
5. The method according to claim 1, characterized in that: The inorganic salts and trace elements include sodium chloride (6000-6800 mg / L), potassium chloride (300-500 mg / L), calcium nitrate tetrahydrate (400-600 mg / L), magnesium sulfate (100-200 mg / L), sodium bicarbonate (1200-3700 mg / L), disodium hydrogen phosphate (100-200 mg / L), copper sulfate pentahydrate (0.01-0.25 mg / L), zinc sulfate heptahydrate (0.1-2.5 mg / L), sodium selenite (0.002-0.05 mg / L), ferric ammonium citrate (0.2-5 mg / L), lithium chloride (0.8-20 mg / L), manganese chloride tetrahydrate (0.0001-0.0025 mg / L), nickel sulfate hexahydrate (0.0001-0.0025 mg / L), and ammonium molybdate tetrahydrate (0.0008-0.02 mg / L). mg / L, sodium metavanadate 0.0001-0.0025 mg / L, stannous chloride dihydrate 0.0008-0.02 mg / L, and sodium metasilicate nonahydrate 0.2-5 mg / L.
6. The method according to claim 1, characterized in that: The lipids include lipoic acid 0.04-1 mg / L, linoleic acid 0.02-0.5 mg / L, oleic acid 0.02-0.5 mg / L and soybean lecithin 0.1-2.5 mg / L.
7. The method according to claim 1, characterized in that: The final concentrations of the growth factors in the whole culture medium were: recombinant human EGF 0.001-0.025 mg / L, recombinant human bFGF 0.001-0.025 mg / L, recombinant human PDGF-AA 0.001-0.025 mg / L, recombinant human PDGF-BB 0.001-0.025 mg / L, recombinant human TGF-β3 0.0001-0.0025 mg / L, recombinant human VEGF165 0.002-0.05 mg / L, and recombinant human LIF 0.002-0.05 mg / L.
8. The method according to claim 1, characterized in that: The other components include glucose 1000-4000 mg / L, sodium pyruvate 55-220 mg / L, malic acid 25-100 mg / L, HEPES 1500-6000 mg / L, recombinant human serum albumin 500-2000 mg / L, recombinant human insulin 5-20 mg / L, recombinant human deferferrin 15-60 mg / L, ethanolamine hydrochloride 5-20 mg / L, sodium β-glycerophosphate 200-400 mg / L, sodium hypoxanthine 3-12 mg / L, thymidine 5-20 mg / L, nicotinamide mononucleotide 5-20 mg / L, and flavin adenine disodium salt dihydrate 3-12 mg / L.
9. The method according to claim 1, characterized in that: The final concentrations of some components in the complete culture medium are as follows: arginine hydrochloride 100 mg / L, asparagine monohydrate 50 mg / L, cystine dihydrochloride 20 mg / L, histidine dihydrochloride 30 mg / L, isoleucine 50 mg / L, leucine 50 mg / L, lysine hydrochloride 60 mg / L, methionine 15 mg / L, phenylalanine 30 mg / L, threonine 50 mg / L, tryptophan 10 mg / L, tyrosine 30 mg / L, valine 50 mg / L, glutamine 300 mg / L, acetylcysteine 150 mg / L, taurine 125 mg / L, γ-aminobutyric acid 10 mg / L, choline chloride 20 mg / L, calcium pantothenate 5 mg / L, calcium leucovorin hydrate 1 mg / L, nicotinamide 5 mg / L, pyridoxal hydrochloride 5 mg / L, thiamine hydrochloride 5 mg / L, cyanocobalamin 0.1 mg / L, inositol 10 mg / L. mg / L, disodium tocopherol phosphate 2 mg / L, potassium chloride 400 mg / L, calcium nitrate tetrahydrate 500 mg / L, magnesium sulfate 150 mg / L, sodium bicarbonate 2450 mg / L, disodium hydrogen phosphate 150 mg / L, zinc sulfate heptahydrate 0.5 mg / L, ferric ammonium citrate 1 mg / L, lithium chloride 4 mg / L, sodium metasilicate nonahydrate 1 mg / L, soybean lecithin 0.5 mg / L, glucose 2000 mg / L, sodium pyruvate 110 mg / L, malic acid 50 mg / L, HEPES 3000 mg / L, recombinant human serum albumin 1000 mg / L, recombinant human deferferrin 30 mg / L, ethanolamine hydrochloride 10 mg / L, β-glycerophosphate sodium 300 mg / L, hypoxanthine sodium 6 mg / L, thymidine 10 mg / L, nicotinamide mononucleotide 10 mg / L, and flavin adenine disodium salt dihydrate 6 mg / L mg / L.
10. The method according to claim 1, characterized in that: The amounts of stock solutions added to the complete culture medium were as follows: 10 mg / L recombinant human EGF 0.5 mL / L, 10 mg / L recombinant human bFGF 0.5 mL / L, 10 mg / L recombinant human PDGF-AA 0.5 mL / L, 10 mg / L recombinant human PDGF-BB 0.5 mL / L, 10 mg / L recombinant human TGF-β3 0.05 mL / L, 10 mg / L recombinant human VEGF165 1 mL / L, 10 mg / L recombinant human LIF 1 mL / L, 1 g / L recombinant human fibronectin 5 mL / L, 1 g / L recombinant human hyalin 5 mL / L, 1 g / L recombinant human laminin 511 1 mL / L, 20 g / L recombinant human type III collagen 5 mL / L, 20 g / L recombinant human fetoglobulin 5 mL / L, insulin concentrate 1 mL / L, concentrate 1 1 mL / L, concentrate 2 0.01 mL / L and concentrate 3 0.01 mL / L.
Citation Information
Patent Citations
Large-scale culture method for umbilical cord mesenchymal stem cells
CN111304163A
